Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tillotson, G. S.
Right arrow Articles by Peterson, L. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tillotson, G. S.
Right arrow Articles by Peterson, L. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 45, 709-710
© 2000 The British Society for Antimicrobial Chemotherapy

Correspondence

Quinolones and pneumococci

G. S. Tillotsona and L. R. Petersonb,*

a Bayer AG, Wuppertal, Germany; b Department of Pathology and Medicine, Northwestern University Medical School, Chicago, IL 60611, USA

Sir,

The recent leading article by Legg & Bint,1 addressing quinolones and pneumococci, raised several key points and ended on a crucial hypothesis for the future treatment of respiratory tract infections (RTIs). The role of fluoroquinolones in RTI therapy has been, at times, an emotionally charged one, perhaps because of the widespread, successful use of these compounds. A major reason for the remarkable chemical evolution of . . . [Full Text of this Article]

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
T. M. File Jr, B. Schlemmer, J. Garau, M. Cupo, C. Young, and the 049 Clinical Study Group
Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin
J. Antimicrob. Chemother., July 1, 2001; 48(1): 67 - 74.
[Abstract] [Full Text] [PDF]